Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 1/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 2/20 | 0.43 |
| ▸ | CA1 | P00915 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | CA7 | P43166 | 2/20 | 0.43 |
| ▸ | CA9 | Q16790 | 2/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.43 |
| ▸ | ESR1 | P03372 | 1/20 | 0.43 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.43 |
| ▸ | CDC7 | O00311 | 3/20 | 0.42 |
| ▸ | DBF4 | Q9UBU7 | 3/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28061402 | 0.86 | SOAT1 (0.44) | HDAC4HDAC6CYP1A2TSHRKMT2A | |
| SCHEMBL1415222 | 0.80 | GAA (0.44) | TSHRKMT2APKMCYP3A4LMNA | |
| SCHEMBL22430810 | 0.77 | TDP1 (0.56) | TSHRKMT2ACYP3A4LMNAALDH1A1 | |
| SCHEMBL13450125 | 0.76 | NPC1 (0.41) | KMT2ALMNAGAAGFERALDH1A1 | |
| SCHEMBL27814361 | 0.74 | KMT2A (0.41) | KMT2ACA12CA1CA2CA9 | |
| SCHEMBL449698 | 0.74 | HDAC4 (0.73) | HDAC4HDAC6CYP1A2TSHRKMT2A | |
| SCHEMBL28287255 | 0.72 | KMT2A (0.39) | KMT2ALMNAGAAGFERALDH1A1 | |
| SCHEMBL363895 | 0.71 | ALDH1A1 (0.40) | HDAC4HDAC6CYP1A2TSHRKMT2A | |
| SCHEMBL752460 | 0.71 | SMN1; SMN2 (0.43) | KMT2APKMCA12CA1CA2 | |
| SCHEMBL29617026 | 0.71 | HDAC4 (0.64) | HDAC4HDAC6CYP1A2TSHRKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1150565-A1 | THIAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF | LION bioscience AG (DE) | 2001-11-07 | — | — | EP | claimed |
| WO-2000045635-A1 | THIAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF | LION BIOSCIENCE AG (DE) | 2000-08-10 | — | — | WO | claimed |
| EP-2493866-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS | Bristol-Myers Squibb Company (US) | 2012-09-05 | — | — | EP | disclosed |
| WO-2011059784-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-05-19 | — | — | WO | disclosed |
| US-20110009428-A1 | NOVEL ANDROGENS | N.V. ORGANON (NL) | 2011-01-13 | — | — | US | disclosed |
| US-7812036-B2 | Androgens | N.V. ORGANON (NL) | 2010-10-12 | — | — | US | disclosed |
| EP-1742912-B1 | NOVEL ANDROGENS | ORGANON NV (NL) | 2010-08-25 | — | — | EP | disclosed |
| US-20070225352-A1 | Novel Androgens | PHARMACOPELA DRUG DISCOVERY, INC. (US) | 2007-09-27 | — | — | US | disclosed |
| EP-1742912-A1 | NOVEL ANDROGENS | N.V. Organon (NL) | 2007-01-17 | — | — | EP | disclosed |
| WO-2005102998-A1 | NOVEL ANDROGENS | N.V. ORGANON (NL) | 2005-11-03 | — | — | WO | disclosed |
| EP-1261327-B1 | ADENOSINE RECEPTOR MODULATORS | HOFFMANN LA ROCHE (CH) | 2005-04-27 | — | — | EP | disclosed |
| US-6809101-B2 | RNA POLYMERASES INHIBITORS; SUCH AS 5-(1-HYDROXY-1-(5-METHYL-OXAZOL-2-YL))METHYLENE-2-THIOXOTHIAZOLIDIN-4-ONE | SHIONOGI & CO., LTD. (JP) | 2004-10-26 | — | — | US | disclosed |
| US-20030203948-A1 | Compounds having anti-hepatitics c virus effect | Z-KAT, INC. | 2003-10-30 | — | — | US | disclosed |
| US-6586441-B2 | 2-Amino-6-benzylsulfanyl-4-thiophen-2-yl-pyridine-3,5-dicarbo -nitrile as an examplary preferred compound; Alzheimer's and Parkinson's diseases; neuroprotectors; schizophrenia, analgesics; anxiolytic agents; respiratory disorders | HOFFMAN-LA ROCHE INC. | 2003-07-01 | — | — | US | disclosed |
| EP-1261327-A2 | ADENOSINE RECEPTOR MODULATORS | F.HOFFMANN-LA ROCHE AG (CH) | 2002-12-04 | — | — | EP | disclosed |
| EP-1150565-A1 | THIAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF | LION bioscience AG (DE) | 2001-11-07 | — | — | EP | disclosed |
| US-20010027196-A1 | Adenosine receptor ligands and their use in the treatment of disease | F. HOFFMANN-LA ROCHE AG (CH) | 2001-10-04 | — | — | US | disclosed |
| WO-2001062233-A2 | ADENOSINE RECEPTOR MODULATORS | F. HOFFMANN LA ROCHE AG (CH) | 2001-08-30 | — | — | WO | disclosed |
| WO-2001021599-A1 | CASPASE INHIBITOR | LG CHEMICAL LTD. (KR) | 2001-03-29 | — | — | WO | disclosed |
| WO-2000045635-A1 | THIAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF | LION BIOSCIENCE AG (DE) | 2000-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225352-A1 | Novel Androgens | NR5A1, AR, SHBG | HDAC4 305/4885HDAC6 247/4885CYP1A2 281/4885 |
| US-20010027196-A1 | Adenosine receptor ligands and their use in the treatment of disease | ADORA2A, ADORA2B, ADORA1 | HDAC4 1236/4885HDAC6 1816/4885CYP1A2 339/4885 |
| US-20110009428-A1 | NOVEL ANDROGENS | NR5A1, AR, NR3C2 | HDAC4 916/4885HDAC6 1016/4885CYP1A2 677/4885 |
| US-20030203948-A1 | Compounds having anti-hepatitics c virus effect | NSUN3, HCCS, NSUN2 | HDAC4 3008/4885HDAC6 1369/4885CYP1A2 816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.